Back

Thymidine rescues ATR kinase inhibition induced deoxyuridine contamination in genomic DNA, cell death, and Type 1 interferon expression

Sugitani, N.; Vendetti, F. P.; Cipriano, A. J.; Pandya, P.; Deppas, J. J.; Moiseeva, T. N.; Schamus-Haynes, S.; Wang, Y.; Palmer, D.; Osmanbeyoglu, H. U.; Bostwick, A.; Snyder, N. W.; Gong, Y.-N.; Aird, K. M.; Delgoffe, G. M.; Beumer, J. H.; Bakkenist, C. J.

2022-08-05 cancer biology
10.1101/2022.02.24.481821 bioRxiv
Show abstract

ATR kinase is a central regulator of the DNA damage response (DDR) and cell cycle checkpoints. ATR kinase inhibitors (ATRis) combine with radiation to generate CD8+ T cell-dependent responses in mouse models of cancer. We show that ATRis induce CDK1-dependent origin firing across active replicons in CD8+ T cells activated ex vivo while simultaneously decreasing the activity of rate-limiting enzymes for nucleotide biosynthesis. These pleiotropic effects of ATRi induce deoxyuridine (dU) contamination in genomic DNA, R loops, RNA-DNA polymerase collisions, and type-1 interferons (IFN-1). Remarkably, thymidine rescues ATRi-induced dU contamination, cell death, and IFN-1 expression in proliferating CD8+ T cells. Thymidine also rescues ATRi-induced cancer cell death. We propose that ATRi-induced dU contamination contributes to dose-limiting leukocytopenia and inflammation in the clinic and CD8+ T cell dependent anti-tumor responses in mouse models. We conclude that ATR is essential to limit dU contamination in genomic DNA and IFN-1 expression.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.